Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -3.94M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.34M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -12.92M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.13M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 42.47K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 3.29M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.84M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.91M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.91M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -6.56K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 7.35M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$2.47B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
44 Neutral | AU$86.98M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$143.13M | -10.00 | -70.29% | ― | ― | -257.32% | |
41 Neutral | AU$45.74M | -2.66 | -180.06% | ― | -14.25% | -22.83% | |
39 Underperform | AU$14.89M | -1.00 | -372.27% | ― | 126.62% | 33.53% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Ltd has lodged a notice of change of interests of a substantial holder under Australia’s Corporations Act, indicating an update to a major shareholder’s voting power in the company. The filing, signed by Chief Operating Officer Keith McLachlan and effective 19 March 2026, reflects altered relevant interests and associations among substantial holders, signalling a shift in the company’s ownership structure that may influence future governance dynamics and investor positioning.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has disclosed a change in director Thomas Duthy’s indirect holdings following his participation in a recent capital raising. Through CIPA Investments Pty Ltd, Duthy acquired 50,537 new shares at $0.68 each, along with 50,537 free-attaching options exercisable at $0.90 and expiring on 30 June 2027, via a placement and entitlement offer.
As a result of the transaction, Duthy’s indirect interest increased to 91,604 shares and 223,348 options in OncoSil Medical. The placement component of his participation had been approved by shareholders at the Extraordinary General Meeting held on 12 March 2026, underscoring board and investor alignment on the company’s latest funding initiative and the director’s reinforced financial commitment.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has disclosed a late lodgement of an Appendix 3Y relating to CEO and managing director Nigel Lange, reflecting the lapse and cancellation of certain performance rights and employee loan-funded shares in line with their terms. The company attributed the delay to an administrative oversight, stressed that directors understand their disclosure obligations under ASX Listing Rules, cited existing securities trading policies, and characterised the event as an isolated incident, indicating confidence in its current compliance controls.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has had its OSLOE class securities reinstated to quotation on the Australian Securities Exchange following confirmation of compliance with ASX Listing Rule 2.5. The resumption of trading restores liquidity and market access for holders of this security class, signalling that the company has met the exchange’s regulatory requirements.
The reinstatement may improve investor confidence and facilitate capital market engagement for OncoSil Medical, as trading in the affected securities resumes under normal conditions. This development clarifies the company’s standing with the exchange and may influence market perceptions of its governance and operational compliance.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has raised new equity by issuing 4,100,470 fully paid ordinary shares at $0.68 each to sophisticated and institutional investors via a placement, providing additional capital to support its interventional oncology business. The shares were issued without a prospectus under Australian disclosure exemptions, with the company confirming compliance with its financial reporting and continuous disclosure obligations under the Corporations Act.
The cleansing notice confirms that no excluded information is being withheld from the market, aiming to ensure that the newly issued shares can be freely traded and that existing and new investors have a level information playing field. The move reinforces OncoSil’s access to institutional capital as it continues commercial rollout of its pancreatic cancer device portfolio in key global markets, potentially strengthening its financial position and strategic flexibility.
The company’s leadership authorised the announcement, signalling board-level support for the capital management initiative and its alignment with broader corporate objectives. By tapping sophisticated and institutional investors, OncoSil also underscores ongoing professional investor interest in its specialised oncology technology and international growth trajectory.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has disclosed the top 20 holders of its listed options, exercisable at $0.90 and expiring on 30 June 2027, which collectively control 86.28% of the 12,082,126 options on issue. The largest positions are held by institutional nominee and custody entities such as BNP Paribas, UBS, Citicorp and HSBC, signalling that the company’s option register is highly concentrated among professional and platform investors, a structure that can influence future capital raising dynamics and market liquidity for these securities.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has applied for quotation on the ASX of 2,951,918 new fully paid ordinary shares and an equal number of deferred options expiring on 30 June 2027. The new securities, issued on 17 March 2026 and linked to a previously announced transaction, will expand the company’s tradable capital base and may influence liquidity and investor positioning in the stock.
The application under Appendix 2A formalises the transition of these securities to quoted status on the Australian Securities Exchange under ticker OSL. This step reflects ongoing capital management activities that could support OncoSil Medical’s operational and strategic initiatives in the medical technology and oncology markets.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has applied for quotation on the ASX of 29,509 new ordinary fully paid shares, to be issued on March 17, 2026. The securities are being quoted as part of previously announced transactions, indicating only a minor increase in the company’s share count and suggesting limited immediate dilution or strategic shift for existing shareholders.
The modest size of the issuance implies it is likely related to routine corporate matters such as employee incentives, fee payments, or small transactional adjustments. For investors, the announcement signals incremental capital or equity housekeeping rather than a major fundraising or transformative corporate action, with minimal expected impact on market positioning or control.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has lodged an application with the ASX for quotation of 306,678 deferred options, designated as OSLOE and expiring on June 30, 2027, with an issue date of March 17, 2026. The options are being quoted as securities issued under a previously announced transaction, indicating a continuation of the company’s established capital management and financing strategy within the public markets.
This move modestly expands the company’s quoted securities base and may provide additional leverage for future funding or incentive structures. For investors and other stakeholders, the quotation of these options clarifies the tradable instruments on issue and underscores OncoSil’s ongoing engagement with equity-based mechanisms to support its operational and strategic objectives.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has applied to the ASX for quotation of 4,100,470 new ordinary fully paid shares and 8,823,530 deferred options expiring on 30 June 2027. The securities, issued on 17 March 2026 as part of previously announced transactions, expand the company’s listed capital base and may influence its funding capacity and share liquidity for existing and prospective investors.
The move reflects ongoing capital management initiatives that could support future operational or strategic activities, even though specific deployment of funds is not detailed. For stakeholders, the additional quoted equity and options adjust the company’s capital structure and may have implications for ownership dilution, trading dynamics, and the valuation framework applied by the market.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has completed a fully subscribed non-renounceable entitlement offer, raising about $2 million including the underwritten portion, to support clinical trials, manufacturing, sales and marketing, market access initiatives and working capital. Around 6% of eligible shareholders participated, with the shortfall taken up by underwriter Bell Potter Securities, and the new shares and options—exercisable at $0.90 and expiring 30 June 2027—are set to trade on the ASX, bolstering the company’s funding base as it advances commercialisation of its pancreatic cancer device.
The entitlement offer issued one new share for every 6.4 existing shares at $0.68, plus one option per new share, resulting in 2,951,918 new shares and an equal number of options. Valid shareholder applications, including top-up bids, accounted for 2,040,217 shares, with the remaining 911,701 allocated to the underwriter, strengthening OncoSil’s capital structure as it seeks to expand its footprint in key oncology markets.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd, an interventional oncology specialist focused on device-based treatments for advanced pancreatic cancer, has developed its OncoSil device to deliver targeted radiotherapy via Phosphorous-32 microparticles, and holds marketing approvals across over 30 countries including key European markets. The technology aims to improve outcomes in a cancer type with typically late diagnosis and poor long-term survival prospects.
The company reported that all resolutions put to shareholders at its 12 March 2026 extraordinary general meeting were passed by poll with strong voting support, including approvals related to placement shares, options, director participation in placements and remuneration shares for the CEO. The results clear the way for OncoSil to proceed with its capital-raising and incentive structures, supporting ongoing commercial rollout and corporate initiatives in its target oncology markets.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
The Australian Securities Exchange has suspended quotation of a specific class of OncoSil Medical Ltd securities, identified by the code OSLOE, under Listing Rule 17.3.4 pending the company’s compliance with Listing Rule 2.5. The suspension affects only this particular class of securities and does not impact any of OncoSil Medical’s other quoted securities, limiting the immediate effect to holders of the OSLOE class.
ASX Compliance issued the suspension notice, signalling regulatory concerns focused on listing rule compliance for this security class rather than the company’s overall listing status. Investors in other OncoSil securities remain unaffected in terms of trading status, though the action may prompt closer scrutiny of the company’s adherence to ASX requirements.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.61 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has opened its entitlement offer to eligible shareholders, confirming that the prospectus and personalised entitlement and acceptance forms have been dispatched and that applications will be accepted until 5:00 p.m. AEDT on 10 March 2026. The timetable outlines expected dates for the close of the offer, an extraordinary general meeting on 12 March, and the subsequent allotment and trading of new shares and options, which are subject to shareholder approval for various placement-related securities.
The company will send a notice of extraordinary general meeting to shareholders, seeking approval for elements of the capital raising structure including director participation, tranche two placement shares and lead manager options. The capital raising via the entitlement offer and associated placement is a key step in strengthening OncoSil Medical’s balance sheet, potentially supporting its commercial expansion in pancreatic cancer treatment markets where its device is already approved and in use.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has applied for quotation on the ASX of 4,723,060 additional ordinary fully paid shares, with an issue date of 9 February 2026. The new securities arise from transactions previously notified to the market, modestly expanding the company’s quoted capital base and potentially affecting liquidity and shareholder holdings once admitted to trading.
The application confirms compliance with ASX Listing Rules for quotation, indicating that the issuance follows standard market processes. While the announcement contains limited operational detail, it signals incremental capital structure activity that may support ongoing corporate or financing arrangements previously disclosed to investors.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has raised new equity by issuing 4,723,060 fully paid ordinary shares at A$0.68 each to sophisticated and institutional investors via an institutional placement. The company stated that the shares were issued without a prospectus under the Corporations Act disclosure exemptions and confirmed it is compliant with its financial reporting and continuous disclosure obligations, with no excluded information on foot, effectively clearing the new stock for on-market trading.
The cleansing notice underscores that OncoSil remains in good standing with corporate governance and disclosure requirements, which may reassure investors about transparency as the company funds its commercial and clinical activities. The capital injection strengthens OncoSil’s balance sheet as it seeks to expand adoption of its CE-marked breakthrough pancreatic cancer device across existing and new markets, potentially supporting further commercial roll-out and regulatory or clinical initiatives.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical announced the resignation of joint company secretary David Wood, leaving Tim Luscombe as the sole company secretary responsible for ASX communications, underscoring continuity in the company’s governance framework amid its ongoing efforts to commercialize its pancreatic cancer treatment device.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has updated details of its proposed non-renounceable pro rata issue of securities, lodging an amended Appendix 3B with the ASX. The company has revised the timetable for the offer, pushing back a key date from 12 March 2025 to 17 March 2025, and has also corrected the offer price of the retail offer options from $0.68 per security to $0.00, effectively indicating that the options will be issued at no subscription price. These changes clarify the commercial terms and timing of the capital raising structure, which may affect investor expectations and the attractiveness of participation in the retail component of the offer.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced a proposed issue of up to 4,723,060 new fully paid ordinary shares under a placement or similar capital-raising mechanism, with an intended issue date of 9 February 2026. The additional securities, to be quoted on the ASX under code OSL, signal a move to raise fresh equity capital, which may impact the company’s capital structure and existing shareholders’ dilution while providing funding flexibility for its ongoing corporate and operational needs.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has released a prospectus for a fully underwritten, non-renounceable pro-rata entitlement offer to raise up to approximately $2 million before costs, issuing one new share for every 6.4 shares held at $0.68 per share, with one new option attached to each new share. The capital raising structure also includes additional option offers to certain placement investors and to the lead manager, Bell Potter Securities, underscoring the company’s need for new funding while highlighting the speculative nature of the investment and the standard legal and risk disclaimers typical of such offers.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has secured firm commitments for an $8 million capital raising, comprising a $6 million two-tranche placement to institutional and professional investors and a fully underwritten $2 million non-renounceable entitlement offer, both priced at $0.68 per share with attaching options. The raise, backed by substantial shareholders including Pengana High Conviction Equities Fund and with participation from directors, will lift pro forma cash to about $12 million to fund ongoing commercial roll-out, regulatory activities and key clinical milestones, notably a German government-sponsored G-BA trial involving around 40 hospitals set to begin recruiting in the first half of 2026, expected to generate trial-related revenues and support broader European reimbursement and guideline inclusion, while momentum continues in other European markets and label expansion submissions progress.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical reported strong early real-world clinical outcomes from Ankara Bilkent City Hospital in Türkiye, where six patients with unresectable locally advanced pancreatic cancer were treated with the OncoSil™ device alongside standard FOLFIRINOX chemotherapy. The cohort achieved one complete response, four partial responses and one stable disease case, with 83% of patients subsequently undergoing successful surgical resection with curative intent—a rate materially higher than published benchmarks for chemotherapy alone and previous OncoSil™ trial data. The company said these results underscore the potential of its device to significantly improve resection rates in a patient group that typically has limited options, bolstering its commercial strategy as it continues to drive broader international adoption and build real-world evidence to support wider clinical use.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical reported a pivotal second quarter of FY26, delivering record dose sales, with unit volumes up 60% and revenue rising 70% year-on-year, underscoring accelerating clinical adoption and strengthening market presence. The company completed its first commercial OncoSil™ treatments in Portugal, Germany and the UK, advanced European rollout with a successful production run at its new Sydney facility, received a $1.8 million R&D tax incentive to support ongoing development, reported encouraging real-world survival data from its OSPREY registry analysis, and announced the retirement of Non-Executive Director and former Chair Douglas Cubbin, collectively reinforcing its operational momentum and manufacturing capability in the pancreatic cancer treatment market.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has requested an immediate trading halt in its securities on the ASX as it prepares to announce a capital raising. The halt will remain in place until the company releases details of the capital raising or until the start of normal trading on 3 February 2026, whichever comes first, signalling a pending move to secure new funding that could impact its capital structure and future operations.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has completed the Last Patient, Last Visit milestone in its TRIPP-FFX clinical trial, a prospective multi-centre study assessing the safety and efficacy of the OncoSil™ device when used alongside FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer. With 88 patients enrolled across 15 sites in Europe and Australia, the company will now move to final data cleaning, database lock and statistical analysis, and plans to present results in the first half of 2026, followed by a regulatory submission in the second half of 2026 to extend its CE Mark to include use with FOLFIRINOX. Together with completion of the PANCOSIL investigator-initiated study, this marks the end of a major phase of clinical investment in this indication and positions OncoSil to concentrate on regulatory engagement, potential label expansion and broader commercial execution, potentially giving clinicians more flexibility to integrate the device into standard treatment pathways for a high unmet-need cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has announced the first successful OncoSil™ treatment at Vivantes Neukölln Hospital in Berlin, one of the largest hospitals in Germany and a leading centre for gastrointestinal oncology within the country’s largest municipal hospital group. The hospital is the second in Germany to adopt the OncoSil™ device, marking a key milestone in the company’s expansion in a strategically important market with a high incidence of pancreatic cancer and a strong network of tertiary referral centres. The new site reinforces growing clinical interest in the therapy, supports OncoSil’s strategy to build clinical momentum and physician awareness ahead of an upcoming German reimbursement trial, and is expected to accelerate adoption across Germany and the wider European region.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has completed the first treatment using its OncoSil™ device at Acibadem Maslak Hospital in Istanbul, marking a key milestone in its international expansion strategy. Türkiye, with around 8,500 new pancreatic cancer cases annually and a sophisticated, fast-adopting private healthcare sector, is seen as a strategically important growth market, and establishing clinical use at a flagship institution within the Acibadem Health Group is expected to build awareness, clinical momentum and broader regional uptake of the therapy for patients with unresectable locally advanced pancreatic cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical announced that a peer‑reviewed study in Gastrointestinal Endoscopy found that patients with locally advanced pancreatic cancer treated with the OncoSil™ phosphorus‑32 implant plus chemotherapy experienced better outcomes than those receiving chemotherapy alone, with improved overall survival, longer local progression‑free survival, higher rates of tumour downstaging and surgical resection, and a favourable safety profile in a 104‑patient analysis. The study, conducted by teams in Australia and New Zealand and accompanied by a positive independent editorial describing the results as “a signal worth pursuing,” strengthens the clinical evidence base for OncoSil™ therapy and supports the company’s ongoing clinical development efforts, potentially enhancing its positioning in the pancreatic cancer treatment landscape and offering encouraging signals for clinicians and patients facing limited options.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has received a A$1.84 million refund under Australia’s R&D Tax Incentive program for eligible research and development activities conducted in the 2025 financial year, reinforcing government-backed support for its ongoing innovation in pancreatic cancer treatment. The company said the non-dilutive funding will help advance its commercial-stage OncoSil™ device, as management focuses on boosting clinician awareness and adoption to drive sales growth and shareholder value while maintaining fiscal discipline, underlining its efforts to strengthen its position in the niche market for localised pancreatic cancer therapies.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd, an ASX-listed oncology-focused medical company, develops and commercialises cancer treatment technologies and related medical devices.
The company has notified the cessation of 7,500 OSLAR options, which were due to expire in November 2028 with an exercise price of $12.00, after the conditional rights attached to these securities lapsed because the required conditions were not, or could no longer be, satisfied, resulting in a minor adjustment to the company’s issued capital structure.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.